Navigation Links
PDL BioPharma Appoints David Montez as Controller and Chief Accounting Officer
Date:7/24/2013

INCLINE VILLAGE, Nev., July 24, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed David Montez, CPA, as controller and chief accounting officer.  Mr. Montez's appointment is effective as of today. 

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

"Dave brings more than 13 years of experience in overseeing accounting and financial functions across  public and private companies and public accounting firms, and we are pleased to welcome him to our team," stated Peter Garcia, vice president and chief financial officer of PDL BioPharma.  "We believe that his knowledge of accounting and financial reporting procedures will enhance and further strengthen our finance team."

Mr. Montez joins PDL from GlassPoint Solar, Inc., where he served as director of finance and corporate controller managing a large team and the company's reporting processes.  Prior to that, Mr. Montez served for six years at Moss Adams LLP as an audit senior manager.  As a partner candidate, he managed and mentored over 80 people during his tenure there and provided consulting and audit services to multiple companies, many of which were in the life sciences sector.  Previously, he was controller at Harmonic Inc. and senior associate at PricewaterhouseCoopers LLP.  Mr. Montez is a licensed certified public accountant (CPA) and holds a BA in Accounting from the University of Utah.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset man
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... and MENLO PARK, Calif. , ... Inc. (OTCQB: DMPI) ("DelMar" "the Company") today announced ... statements.  The Company recently changed its fiscal year end ... to list its common stock on a national securities ... financial statements as filed with the United States Securities ...
(Date:8/29/2014)... AMSTERDAM , August 29, 2014 ... invited to participate in the inaugural Tweetchat taking ... CPhI Worldwide , organised by UBM ... October 2014. #CPhIChat is a first of its ... media working across the supply chain, aimed to ...
(Date:8/28/2014)... 2014  Rigrodsky & Long, P.A.: , Do ... LCI )? , Did you purchase your shares ... 16, 2014, inclusive? , Did you lose money in ... want to discuss your rights? Rigrodsky ... Timothy J. MacFall , announces that a complaint has been ...
Breaking Medicine Technology:DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... March 31, 2011 Reportlinker.com announces that ... in its catalogue: Gout ... Therapies such as Krystexxa, Uloric, Adenuric and ... http://www.reportlinker.com/p0464105/Gout-Therapeutics-Market-to-2017--Entry-of-Novel-Therapies-such-as-Krystexxa-Uloric-Adenuric-and-Colcrys-to-Drive-Market.html Gout Therapeutics ...
... that a new market research report is available in ... Testing Markets http://www.reportlinker.com/p089570/Cardiac-Marker-Diagnostic-Testing-Markets.html ... is to describe the specific market segment of the ... testing. This study examines clinical measurement devices and their ...
Cached Medicine Technology:Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 2Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 3Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 4Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 5Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 6Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 7Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 8Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 9Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 10Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 11Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 12Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 2Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 3Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 4Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 5Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 6Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 7Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 8
(Date:8/30/2014)... Colorado Springs, CO (PRWEB) August 30, 2014 ... valuable, and increasingly difficult to get. Snoring and sleep apnea ... breathing stops) rob people and their bed partners of the ... Up to 45% of the population snores and 20 million ... these, only 10% have been diagnosed and treated; and of ...
(Date:8/30/2014)... 2014 "My niece developed a nighttime ... any moment, her fever might get worse," said an ... well aware of how she was doing, I developed ... to continuously monitor a child's temperature. The unit instantly ... ensures that prompt medical care can be given, which ...
(Date:8/30/2014)... Transvenous lead extraction (TLE) is clinically successful in more ... European Lead Extraction ConTRolled (ELECTRa) registry presented for the ... Maria Grazia Bongiorni, chair of the registry,s executive committee. ... electronic devices (CIED) implant procedures has grown in recent ... has increased and leads are often the cause. TLE ...
(Date:8/30/2014)... The new review published by Daily Gossip reveals that the ... wanted to make her guide accessible to sufferers from all ... to find in the form of an eBook, which is ... the new method shares all her tips and recommendations for ... review that the leaky gut syndrome can be an extremely ...
(Date:8/30/2014)... 2014 Jake W., 18, is completing his ... Back2Basics Outdoor Adventures transition program known as Beyond ... so I can actually start on a real career path,” ... I'm done.” , He has six months of sobriety under ... clients choose to continue on to the Beyond the Basics ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2
... Founder of ... who accelerated her recovery. Lack of friends connected to poorer health Company aims to reduce ... ... The Friendship Stone will mark Friendship Week starting August 2nd. Founder, Cathy Raff, will dedicate ...
... , , New Report Is ... Lower Costs , , KANSAS CITY, Mo., ... marks for communicating effectively and treating them respectfully, according to a new patient experience ... 700 doctors are available at http://kcq i c.org ...
... , , OLYMPIA, ... prescription medications since the launch of the free statewide prescription assistance program. ... was launched in August, 2008. The program has no restrictions to membership, ... fill out. Anyone interested in receiving a free card can visit ...
... , , WARSAW, Ind., July ... independent provider of products to the global orthopaedic device industry and other ... results for the period ending July 4, 2009 before the market opens ... call at 8:00 a.m. ET on Thursday, August 6, 2009. , ...
... , , HOUSTON, July 21 US Oncology, ... on Thursday, August 6, 2009. , , A ... ET following distribution of the earnings release. Additional information will be available on ... on the day of the earnings announcement. , , ...
... IHA Completes the Second Chapter of the ... for Measurement Years 2006 - 2009 , ... (IHA) is pleased to announce the publication of "The Second Chapter," a ... for performance (P4P) program - the largest non-governmental physician incentive program in ...
Cached Medicine News:Health News:The Friendship Stone Helps Friends Remain Healthy 2Health News:The Friendship Stone Helps Friends Remain Healthy 3Health News:The Friendship Stone Helps Friends Remain Healthy 4Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 2Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 3Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 4Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 5Health News:Free Drug Card Has Saved Washington Residents $2.6 Million 2Health News:Symmetry Medical to Report Second Quarter 2009 Financial Results on August 6, 2009 2Health News:US Oncology to Report 2009 Second Quarter Operating Results 2Health News:Integrated Healthcare Association Releases White Paper on Pay for Performance 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
Medicine Products: